Puzo Michael J Sells 576 Shares of AbbVie Inc (NYSE:ABBV)
Puzo Michael J decreased its position in shares of AbbVie Inc (NYSE:ABBV) by 3.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,000 shares of the company’s stock after selling 576 shares during the period. Puzo Michael J’s holdings in AbbVie were worth $1,418,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in ABBV. Hoey Investments Inc. bought a new position in shares of AbbVie during the 4th quarter worth about $31,000. Kempen Capital Management N.V. bought a new stake in shares of AbbVie in the second quarter valued at about $41,000. Edge Wealth Management LLC lifted its stake in shares of AbbVie by 106.1% in the third quarter. Edge Wealth Management LLC now owns 573 shares of the company’s stock valued at $43,000 after buying an additional 295 shares during the period. Massey Quick Simon & CO. LLC grew its position in AbbVie by 2,400.0% during the third quarter. Massey Quick Simon & CO. LLC now owns 625 shares of the company’s stock worth $47,000 after buying an additional 600 shares in the last quarter. Finally, Selective Wealth Management Inc. acquired a new stake in AbbVie during the third quarter worth about $48,000. 70.42% of the stock is owned by hedge funds and other institutional investors.
Several research firms have commented on ABBV. Royal Bank of Canada started coverage on AbbVie in a report on Monday, January 6th. They issued a “sector perform” rating and a $86.00 price target for the company. ValuEngine upgraded AbbVie from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Cowen upped their target price on AbbVie from $90.00 to $98.00 and gave the company an “outperform” rating in a research note on Thursday, December 26th. Piper Jaffray Companies raised their target price on AbbVie from $81.00 to $90.00 in a research report on Friday, November 1st. Finally, UBS Group lifted their price target on shares of AbbVie from $79.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. AbbVie currently has a consensus rating of “Hold” and a consensus target price of $86.33.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, November 1st. The company reported $2.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.04. The firm had revenue of $8.48 billion during the quarter, compared to the consensus estimate of $8.37 billion. AbbVie had a net margin of 9.90% and a negative return on equity of 155.96%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $2.14 EPS. As a group, sell-side analysts predict that AbbVie Inc will post 8.95 EPS for the current fiscal year.
The firm also recently declared a — dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a dividend of $1.18 per share. This represents a yield of 5.93%. This is a boost from AbbVie’s previous — dividend of $1.07. The ex-dividend date is Tuesday, January 14th. AbbVie’s dividend payout ratio (DPR) is currently 59.67%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.